Literature DB >> 3497460

Histamine type-2 receptor antagonist immune modulation. II. Cimetidine and ranitidine increase interleukin-2 production.

R R Gifford, A F Tilberg.   

Abstract

The effect of cimetidine and ranitidine (histamine type-2 receptor antagonists) on the production of interleukin-2 (IL-2) by mitogen-activated, normal murine spleen cells was studied in vitro. Cimetidine (10(-4) mol/L to 10(-6) mol/L) increased IL-2 production to a maximal 8.8 +/- 1.6 U (IL-2 activity), as compared with media controls of 1 U. Ranitidine (10(-4) mol/L to 10(-6) mol/L) also increased IL-2 production to a maximal 5.6 +/- 1.2 U, as compared with media controls of 1 U. The increases for both drugs were statistically significant- (p at least less than 0.03 for all doses tested). These data suggest that our previously demonstrated immunofacilitation of proliferative and cytotoxic lymphocyte responses by cimetidine was probably mediated by the presence of increased IL-2. These data further suggest that histamine type-2 receptor antagonists may have immunorestorative potential in clinical immunotherapy of IL-2 deficient states.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497460

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  12 in total

Review 1.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists.

Authors:  A A Fisher; D G Le Couteur
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

3.  A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group.

Authors:  J N Primrose; G V Miller; S R Preston; J Gokhale; N S Ambrose; U M Ward; J G Mills; R S Ehsanullah; B Darekar
Journal:  Gut       Date:  1998-01       Impact factor: 23.059

Review 4.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

5.  Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine.

Authors:  S A Watson; L J Wilkinson; J F Robertson; J D Hardcastle
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

6.  Immunomodulatory effect of cimetidine in common carp (Cyprinus carpio L.).

Authors:  Seyyed Mehdi Hosseinifard; Asieh Ahmadpour; Bagher Mojazi Amiri; Majid Razeghi Mansour; Arezo Ebrahimpour
Journal:  Fish Physiol Biochem       Date:  2013-05-24       Impact factor: 2.794

7.  The effect of ranitidine on cellular immunity in patients with multiple myeloma.

Authors:  H J Nielsen; H Nielsen; F Moesgaard; N Tvede; K Klarlund; B Mansa; A Drivsholm
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.

Authors:  W J Adams; J A Lawson; D L Morris
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

9.  Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients.

Authors:  T Kubota; H Fujiwara; Y Ueda; T Itoh; T Yamashita; T Yoshimura; K Okugawa; Y Yamamoto; Y Yano; H Yamagishi
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

10.  Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth.

Authors:  J A Lawson; W J Adams; D L Morris
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.